Events and core viewpoints

Event: on the evening of March 8, 2019, Zhangjiang in Fudan, Shanghai, announced that the company intends to apply to the relevant regulatory authorities for listing on Kechuang Board in China, issuing no more than 120 million A-shares and intends to raise 650 million yuan.

Core ideas:

The company is an innovative pharmaceutical company characterized by photodynamic drugs, with two photodynamic therapy drugs: Ella (aminolevulinic acid for topical use) and Fumeda (Hympofen for injection). As the first drug approved for the treatment of port wine stains in the world, Helmpofen is expected to make a further breakthrough if it can raise funds from the Kechuang board to complete its registration in the United States.

The company is controlled by state-owned assets and has rich experience in the management industry. The listing of Science and Technology Innovation Board will help to further enhance the company's image, reflect innovation and R & D capabilities, and further expand the company's financing channels.

Risk Tips:

The risk of failure to apply for the listing of Kechuang board, the risk of failure in product research and development, and the risk that product sales are not as expected.